Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population

Steven Kozlowski; Noy Birger; Stephaeno Brereton; Stephen J McKean; Michael Wernecke; Leah Christl; Jeffrey A Kelman

doi:10.1001/jama.2018.9014

Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population

JAMA. 2018 Sep 4;320(9):929-931. doi: 10.1001/jama.2018.9014.

Authors

Steven Kozlowski¹, Noy Birger², Stephaeno Brereton², Stephen J McKean², Michael Wernecke², Leah Christl¹, Jeffrey A Kelman³

Affiliations

¹ Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
² Acumen LLC, Burlingame, California.
³ Centers for Medicare & Medicaid Services, Washington, DC.

Abstract

This study uses Medicare part B billing data to compare trends in the use of filgrastim and its biosimilars among beneficiaries between 2014 and 2016.

MeSH terms

Aged
Aged, 80 and over
Biosimilar Pharmaceuticals / therapeutic use*
Drug Utilization / statistics & numerical data*
Female
Filgrastim / therapeutic use*
Hematologic Agents / therapeutic use*
Humans
Male
Medicare Part B
United States

Substances

Biosimilar Pharmaceuticals
Hematologic Agents
Filgrastim